Geographic Area
Trump pledges his support for a change to the IRA long sought by drugmakers
IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare
J&J brushes off tariff headwinds with raised forecast, oncology surge
J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions
Illumina and Tempus look beyond cancer in new AI-driven genomics deal
Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market
Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly
Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High
Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.
Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay
Hemgenix, SMPX gene, Pfizer, gene therapy, alternatives, HYMPAVZI, Clinical Trials
Novartis to invest $23B in manufacturing so ‘all key medicines’ can be made in the US
Novartis, United States, Investments, Manufacture, production, Biological Factors, Novartis
Pharma stocks swerve as Trump hits pause on most tariffs
Market, Transplant Registry Unified Management Program, Pauses
Novo Nordisk Invests $1.1 Billion to Expand GLP-1 Drug Manufacturing in Brazil
Novo Nordisk , GLP-1 production , Brazil investment , Wegovy and Ozempic , Diabetes treatment , Obesity treatment , Montes Claros facility , Pharmaceutical manufacturing
Global Pharmaceutical Stocks Plummet Amid Trump’s Imminent Tariff Threats
Pharmaceutical tariffs, global pharma stocks, Trump import tariffs, drug manufacturing, supply chain disruption, pharmaceutical trade war, U.S. pharma policy